Using a special patch to prevent oral cancer from precancerous lesions
Assessment of Chemopreventive Effects of a Mucoadhesive Fenretinide Patch on Premalignant Oral Epithelial Lesions
This study is testing a special patch that delivers medication directly to the mouth to see if it can help prevent early signs of oral cancer from getting worse, and it's for people with premalignant oral lesions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10885898 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a mucoadhesive fenretinide patch in preventing the progression of premalignant oral epithelial lesions, known as oral intraepithelial neoplasia (OIN), into oral squamous cell carcinoma (OSCC). The approach focuses on local delivery of the drug directly to the affected area, which aims to achieve higher therapeutic levels while minimizing systemic side effects. Patients will be monitored for changes in their lesions and overall oral health throughout the treatment period. The study seeks to identify which lesions are at higher risk of transformation and to provide a more effective preventive strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with oral intraepithelial neoplasia who are at high risk for developing oral squamous cell carcinoma.
Not a fit: Patients with no history of premalignant oral lesions or those already diagnosed with oral squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of oral cancer in patients with premalignant lesions.
How similar studies have performed: Previous research has shown that local delivery methods can be more effective than systemic approaches in cancer prevention, suggesting potential for success in this novel application.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Mallery, Susan R — Ohio State University
- Study coordinator: Mallery, Susan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.